J3032 Injection. eptinezumab-jjmr 1 milligrams
Also known as: eptinezumab, Vyepti, CGRP receptor antagonist
Eptinezumab-jjmr (Vyepti) 1 milligram injection is a monoclonal antibody targeting calcitonin gene-related peptide receptor for intravenous chronic migraine prevention.
In Plain Language
migraine prevention IV infusion; quarterly migraine treatment
Clinical Context
FDA-approved for chronic migraine prevention, administered intravenously every 12 weeks. Blocks calcitonin gene-related peptide receptor to reduce neuronal inflammation and migraine frequency in chronic migraine patients.
RVU Information
CPT J3032 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J3032?
CPT J3032 (Injection. eptinezumab-jjmr 1 milligrams) is a J Codes (Drugs) code. Eptinezumab-jjmr (Vyepti) 1 milligram injection is a monoclonal antibody targeting calcitonin gene-related peptide receptor for intravenous chronic migraine prevention.
How is J3032 administered?
CPT J3032 is administered by a healthcare provider, typically via injection or infusion. FDA-approved for chronic migraine prevention, administered intravenously every 12 weeks. Blocks calcitonin gene-related peptide receptor to reduce neuronal inflammation and migraine frequency in chronic migraine patients. It is used by Neurology, Pain Management, Infusion Centers.
When is CPT J3032 used?
FDA-approved for chronic migraine prevention, administered intravenously every 12 weeks. Blocks calcitonin gene-related peptide receptor to reduce neuronal inflammation and migraine frequency in chronic migraine patients.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.